Vital KSK Holdings, Inc. ( (JP:3151) ) has issued an update.
Vital KSK Holdings, Inc. has revised its earnings and dividend forecasts for the fiscal year ending March 31, 2025, due to strong performance in its pharmaceutical wholesale business. The company anticipates higher profits attributable to owners of the parent, driven by increased sales and foreign exchange gains, despite some offsetting factors. Additionally, the company has increased its year-end dividend forecast, marking the fourth consecutive year of dividend growth, reflecting its commitment to shareholder returns and achieving its highest annual dividend payment since establishment.
More about Vital KSK Holdings, Inc.
Vital KSK Holdings, Inc. operates in the pharmaceutical wholesale industry, focusing primarily on distributing pharmaceutical products including anti-cancer drugs, vaccines, test kits, and therapeutic drugs. The company is positioned in the market to capitalize on the demand for these products, particularly during health crises such as influenza outbreaks.
YTD Price Performance: -9.19%
Average Trading Volume: 61,191
Technical Sentiment Consensus Rating: Sell
Current Market Cap: Yen51.11B
Learn more about 3151 stock on TipRanks’ Stock Analysis page.